Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 671061, 6 pages
http://dx.doi.org/10.1155/2014/671061
Clinical Study

IGF-1 and ADMA Levels Are Inversely Correlated in Nondiabetic Ankylosing Spondylitis Patients Undergoing Anti-TNF-Alpha Therapy

1Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, 39011 Santander, Spain
2Rheumatology Division, Hospital Lucus Augusti, 27003 Lugo, Spain
3Endocrinology Division, Hospital Clínico Universitario, 47005 Valladolid, Spain
4Oncology Division, Hospital Del Bierzo, Ponferrada, 24411 León, Spain
5Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, IDIVAL and CIBER Epidemiología y Salud Pública (CIBERESP), 39011 Santander, Spain
6Cardiology Division, Hospital Lucus Augusti, 27003 Lugo, Spain
7Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2000, South Africa

Received 9 July 2014; Accepted 20 August 2014; Published 11 September 2014

Academic Editor: Patrick H. Dessein

Copyright © 2014 Fernanda Genre et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Gonzalez-Juanatey, T. R. Vazquez-Rodriguez, J. A. Miranda-Filloy et al., “The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease,” Medicine, vol. 88, no. 6, pp. 358–365, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. A. El Maghraoui, “Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications,” European Journal of Internal Medicine, vol. 22, no. 6, pp. 554–560, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Mathieu, P. Motreff, and M. Soubrier, “Spondyloarthropathies: an independent cardiovascular risk factor?” Joint Bone Spine, vol. 77, no. 6, pp. 542–545, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. F. Genre, R. López-Mejías, J. A. Miranda-Filloy et al., “Adipokines, biomarkers of endothelial activation, and metabolic syndrome in patients with ankylosing spondylitis,” Biomedical Research International, vol. 2014, Article ID 860651, 11 pages, 2014. View at Publisher · View at Google Scholar
  5. S. D'Angelo, C. Palazzi, F. Cantini et al., “Etanercept in spondyloarthropathies. Part II: safety and pharmacoeconomic issues,” Clinical and Experimental Rheumatology, vol. 29, no. 5, pp. 865–870, 2011. View at Google Scholar · View at Scopus
  6. C. Palazzi, S. D'Angelo, F. Cantini et al., “Etanercept in spondyloarthropathies, part I: current evidence of efficacy,” Clinical and Experimental Rheumatology, vol. 29, no. 5, pp. 858–864, 2011. View at Google Scholar · View at Scopus
  7. F. Heldmann, J. Brandt, I. E. van der Horst-Bruinsma et al., “The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long-term outcomes in patients with ankylosing spondylitis treated with infliximab,” Clinical and Experimental Rheumatology, vol. 29, no. 4, pp. 672–680, 2011. View at Google Scholar · View at Scopus
  8. J. S. Smolen and P. Emery, “Infliximab: 12 years of experience,” Arthritis Research and Therapy, vol. 13, article S2, no. 1, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Syngle, K. Vohra, A. Sharma, and L. Kaur, “Endothelial dysfunction in ankylosing spondylitis improves after tumor necrosis factor-α blockade,” Clinical Rheumatology, vol. 29, no. 7, pp. 763–770, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. F. Genre, R. López-Mejias, J. A. Miranda-Filloy et al., “Correlation between insulin resistance and serum ghrelin in non-diabetic ankylosing spondylitis patients undergoing anti-TNF-α therapy,” Clinical and Experimental Rheumatology, vol. 31, no. 6, pp. 913–918, 2013. View at Google Scholar
  11. F. Genre, R. López-Mejías, J. A. Miranda-Filloy et al., “Antitumour necrosis factor α treatment reduces retinol-binding protein 4 serum levels in non-diabetic ankylosing spondylitis patients,” Annals of the Rheumatic Diseases, vol. 73, no. 5, pp. 941–943, 2014. View at Publisher · View at Google Scholar
  12. J. A. Miranda-Filloy, R. López-Mejias, F. Genre et al., “Adiponectin and resistin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy,” Clinical and Experimental Rheumatology, vol. 31, no. 3, pp. 365–371, 2013. View at Google Scholar · View at Scopus
  13. J. A. Miranda-Filloy, R. López-Mejias, F. Genre et al., “Leptin and visfatin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy,” Clinical and Experimental Rheumatology, vol. 31, no. 4, pp. 538–545, 2013. View at Google Scholar
  14. F. Genre, R. López-Mejías, J. A. Miranda-Filloy et al., “Asymmetric dimethylarginine serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy,” Clinical and Experimental Rheumatology, vol. 31, no. 5, pp. 749–755, 2013. View at Google Scholar
  15. F. Genre, J. A. Miranda-Filloy, R. López-Mejias et al., “Antitumour necrosis factor-α therapy modulates angiopoietin-2 serum levels in non-diabetic ankylosing spondylitis patients,” Annals of the Rheumatic Diseases, vol. 72, no. 7, pp. 1265–1267, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. F. Genre, R. López-Mejias, J. A. Miranda-Filloy et al., “Correlation between two biomarkers of atherosclerosis, osteopontin and angiopoietin-2, in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy,” Clinical and Experimental Rheumatology, vol. 32, no. 2, pp. 231–236, 2014. View at Google Scholar
  17. F. Genre, R. López-Mejias, J. A. Miranda-Filloy et al., “Osteoprotegerin correlates with disease activity and endothelial activation in non-diabetic ankylosing spondylitis patients undergoing TNF- α antagonist therapy,” Clinical and Experimental Rheumatology. In press.
  18. F. Genre, J. Rueda-Gotor, and R. López-Mejias, “Patients with ankylosing spondylitis and low disease activity because of anti-TNF-alpha therapy have higher TRAIL levels than controls: a potential compensatory effect,” Mediators of Inflammation, vol. 2014, Article ID 798060, 6 pages, 2014. View at Publisher · View at Google Scholar
  19. E. Toussirot, N. U. Nguyen, G. Dumoulin, J. Regnard, and D. Wendling, “Insulin-like growth factor-I and insulin-like growth factor binding protein-3 serum levels in ankylosing spondylitis,” The British Journal of Rheumatology, vol. 37, no. 11, pp. 1172–1176, 1998. View at Publisher · View at Google Scholar · View at Scopus
  20. V. H. Heemskerk, M. A. Daemen, and W. A. Buurman, “Insulin-like growth factor-1 (IGF-1) and growth hormone (GH) in immunity and inflammation,” Cytokine & Growth Factor Reviews, vol. 10, no. 1, pp. 5–14, 1999. View at Publisher · View at Google Scholar · View at Scopus
  21. P. Delafontaine, Y.-H. Song, and Y. Li, “Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 3, pp. 435–444, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. E. Toussirot and D. Wendling, “Osteoporosis in ankylosing spondylitis,” Presse Medicale, vol. 25, no. 15, pp. 720–724, 1996. View at Google Scholar · View at Scopus
  23. C. Wuster, W. F. Blum, S. Schlemilch, M. B. Ranke, and R. Ziegler, “Decreased serum levels of insulin-like growth factors and IGF binding protein 3 in osteoporosis,” Journal of Internal Medicine, vol. 234, no. 3, pp. 249–255, 1993. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Ljunghall, A. G. Johansson, P. Burman, O. Kampe, E. Lindh, and F. A. Karlsson, “Low plasma levels of insulin-like growth factor 1 (IGF-1) in male patients with idiopathic osteoporosis,” Journal of Internal Medicine, vol. 232, no. 1, pp. 59–64, 1992. View at Publisher · View at Google Scholar · View at Scopus
  25. A. G. Johansson, E. Lindh, W. F. Blum, G. Kollerup, O. H. Sørensen, and S. Ljunghall, “Effects of growth hormone and insulin-like growth factor I in men with idiopathic osteoporosis,” Journal of Clinical Endocrinology and Metabolism, vol. 81, no. 1, pp. 44–48, 1996. View at Publisher · View at Google Scholar · View at Scopus
  26. R. Cimaz, R. Rusconi, B. Cesana et al., “A multicenter study on insulin-like growth factor-I serum levels in children with chronic inflammatory diseases,” Clinical and Experimental Rheumatology, vol. 15, no. 6, pp. 691–696, 1997. View at Google Scholar · View at Scopus
  27. S. van der Linden, H. A. Valkenburg, and A. Cats, “Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria,” Arthritis and Rheumatism, vol. 27, no. 4, pp. 361–368, 1984. View at Publisher · View at Google Scholar · View at Scopus
  28. D. van der Heijde, J. Sieper, W. P. Maksymowych et al., “2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis,” Annals of the Rheumatic Diseases, vol. 70, no. 6, pp. 905–908, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Garrett, T. Jenkinson, L. G. Kennedy, H. Whitelock, P. Gaisford, and A. Calin, “A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index,” The Journal of Rheumatology, vol. 21, no. 12, pp. 2286–2291, 1994. View at Google Scholar · View at Scopus
  30. J. A. Miranda-Filloy, J. Llorca, B. Carnero-López, C. González-Juanatey, R. Blanco, and M. A. González-Gay, “TNF-α antagonist therapy improves insulin sensitivity: in non-diabetic ankylosing spondylitis patients,” Clinical and Experimental Rheumatology, vol. 30, no. 6, pp. 850–855, 2012. View at Google Scholar · View at Scopus
  31. F. Genre, J. A. Miranda-Filloy, R. López-Mejias et al., “Apelin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy,” Clinical and Experimental Rheumatology, vol. 31, no. 4, pp. 532–537, 2013. View at Google Scholar
  32. F. Genre, R. López-Mejias, J. A. Miranda-Filloy et al., “Gelsolin levels are decreased in ankylosing spondylitis patients undergoing anti-TNF-alpha therapy,” Clinical and Experimental Rheumatology, vol. 32, no. 2, pp. 218–224, 2014. View at Google Scholar
  33. E. Setola, L. D. Monti, R. Lanzi et al., “Effects of growth hormone treatment on arginine to asymmetric dimethylarginine ratio and endothelial function in patients with growth hormone deficiency,” Metabolism, vol. 57, no. 12, pp. 1685–1690, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. J. Ren, J. Duan, D. P. Thomas et al., “IGF-I alleviates diabetes-induced RhoA activation, eNOS uncoupling, and myocardial dysfunction,” The American Journal of Physiology: Regulatory Integrative and Comparative Physiology, vol. 294, no. 3, pp. R793–R802, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Takiuchi, H. Fujii, K. Kamide et al., “Plasma asymmetric dimethylarginine and coronary and peripheral endothelial dysfunction in hypertensive patients,” American Journal of Hypertension, vol. 17, no. 9, pp. 802–808, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. J. P. Cooke, “Asymmetrical Dimethylarginine: the Über marker?” Circulation, vol. 109, no. 15, pp. 1813–1818, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Ji, Q. Ma, X. Luo, and J. Peng, “Protective effect of insulin-like growth factor-1 on vascular endothelial function in hypercholesterolemia and the underlying mechanism,” Journal of Central South University: Medical Sciences, vol. 38, no. 1, pp. 36–42, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. U. Lange, J. Teichmann, and H. Stracke, “Correlation between plasma TNF-alpha, IGF-1, biochemical markers of bone metabolism, markers of inflammation/disease activity, and clinical manifestations in ankylosing spondylitis,” European Journal of Medical Research, vol. 5, no. 12, pp. 507–511, 2000. View at Google Scholar · View at Scopus
  39. K. Briot, P. Garnero, A. Le Henanff, M. Dougados, and C. Roux, “Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor α treatment,” Annals of the Rheumatic Diseases, vol. 64, no. 8, pp. 1137–1140, 2005. View at Publisher · View at Google Scholar · View at Scopus